Can small molecule GLP-1 agonists be the next first-line drugs in type-2 diabetes mellitus?

An editorial focuses on the potential of small molecule GLP-1 agonists, specifically orforglipron and danuglipron, to become the next first-line drugs in the management of type-2 diabetes mellitus due to their enhanced efficacy and affordability compared to existing peptide GLP-1 agonists.